Buscar
-
Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample
(Drug Safety. vol. 41, n° 11, pp. 1049-1058, 2018-11)Article de revue -
Inhaled triple therapy in chronic obstructive pulmonary disease
(Lancet. vol. 392, n° 10153, pp. 1112, 2018-09-29)Article de revue -
Use of real-world evidence in translational pharmacology research
(Fundamental & Clinical Pharmacology, 2021-10-21)Article de revue -
Requests for post-registration studies (PRS), patients follow-up in actual practice: Changes in the role of databases
(Thérapie. vol. 73, n° 1, pp. 13-24, 2018-02)Article de revue -
Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases
(The Lancet. Psychiatry. vol. 5, n° 10, pp. 824-835, 2018-10)Article de revue -
Patterns of quadruple therapy use including bismuth for Helicobacter pylori eradication: A cohort study in the French national claims database
(Thérapie. vol. 76, n° 5, pp. 435-440, 2021-09)Article de revue -
Chloroquine for COVID-19 Infection
(Drug Safety. vol. 43, n° 3, pp. 393-394, 2020)Article de revue -
Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS
(Am J Cardiovasc Drugs. vol. 20, n° 1, pp. 81-103, 2020)Article de revue -
Does Ibuprofen Worsen COVID-19?
(Drug Safety. vol. 43, n° 7, pp. 611-614, 2020)Article de revue -
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database
(Atherosclerosis. vol. 281, pp. 98-106, 2019)Article de revue